One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Researchers at Saint Louis University's School of Medicine say T-cell dysfunction is leading to an increased risk of cancer ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...

CAR T-cell therapies for hematologic malignancies have targets ... Additionally, tumor cells exist in a hostile, ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Tumors find different ways to avoid immune cell detection and proliferate in their environment. Antitumor immune cells will ...

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...